top of page

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

info372548

Abstract

BACKGROUND

Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.

METHODS

We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin <85 mg per square meter of body-surface area>, irinotecan <180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis>, leucovorin <400 mg per square meter>, and fluorouracil <2400 mg per square meter> every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety.

RESULTS

At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval , 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis).

CONCLUSIONS

Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135; EudraCT number, 2011-002026-52.) Article by: Thierry Conroy, M.D., Pascal Hammel, M.D., Ph.D., Mohamed Hebbar, M.D., Ph.D., Meher Ben Abdelghani, M.D., Alice C. Wei, M.D., C.M., Jean-Luc Raoul, M.D., Ph.D., Laurence Choné, M.D., Eric Francois, M.D., Pascal Artru, M.D., James J. Biagi, M.D., Thierry Lecomte, M.D., Ph.D., Eric Assenat, M.D., Ph.D., for the Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group

1 view0 comments

Recent Posts

See All

Lisa’s HopkINNS Helps

HopkINNS Helps was created after a conversation I had with a pancreatic cancer patient named David Sokoloff. David had a successful...

Comments


Follow Us

1-615-982-6802

PO Box 68305

Nashville, TN 37206

 

info@nmfcares.org

EIN Tax ID: 46-3399632

images_edited_edited.png
349-3493616_instagram-circle-logo-transp

Subscribe to get exclusive updates

Copyright ©2024 Nikki Mitchell Foundation. All Rights Reserved. Nikki Mitchell Foundation is a registered 501(c)(3) non-profit.

 

The Nikki Mitchell Foundation is a fiscally sponsored project of the Edward Charles Foundation, a 501c3 public non-profit organization (tax ID 26-4245043)

Medical Disclaimer: 
Information is solely intended as educational purpose only. It is not to be considered as a substitute for professional medical advice. We encourage all visitors to consult directly with their physician. Site visitors should not rely on any information contained for health needs. Instead, all questions should be discussed with professional medical doctors.

bottom of page